Category: Press Releases
Kizoo Portfolio Company Cellvie Closes $5.5M of Funding
February 8, 2023
The company cellvie, part of the portfolio of biotechnology holding company Kizoo Technology Capital, recently received $5.5 million to develop a mitochondria-based therapy. The full press release is included here.
Longevity Investors Lunch at Davos
January 24, 2023
A Longevity Investors Lunch hosted by Maximon, Longevity Investors Conference, and Biolytica has been hosted at a satellite event of the well-known Davos conference. The press release is included here.
Open Longevity Foundation Announces Open Genes Database
January 24, 2023
Open Longevity Foundation has announced Open Genes, a database of longevity-associated genes and a tool for future anti-aging therapy development. The full press release is included here. Open Longevity Foundation
Gero Enters Research Collaboration with Pfizer
January 10, 2023
Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale
Immunis Begins Clinical Trial of Stem Cell Secretome
January 5, 2023
Intending to treat sarcopenia, the private biotechnology company Immunis has begun a human clinical trial of a stem cell secretome product that affects the immune system. The company’s full press
Turn Biotechnologies Changes Paradigm in Skin Rejuvenation
December 6, 2022
Turn Biotechnologies has unveiled data at four industry conferences suggesting that a single ERA treatment may be more effective than combination therapies used today. Biomarker analysis demonstrates ERA’s regenerative impact
BioAge Announces Positive Results Against Muscle Atrophy
December 5, 2022
BioAge Labs has concluded a Phase 1b study in which human volunteers undergoing 10 days of bed rest were shown to have their related muscle atrophy significantly attenuated by BGE-105.
Longevity Biotech Fellowship Announces Launch
November 21, 2022
On Deck Longevity Biotech and the founders of LessDeath.org have collaborated to start the Longevity Biotech Fellowship, a new initiative focusing on bringing upcoming professionals into the longevity industry. The
The Quantum Healthy Longevity Innovation Mission Launches
November 14, 2022
London. 14 November 2022. The National Innovation Centre for Ageing and Collider Health launch the Quantum Healthy Longevity Innovation Mission with a keynote by Lord Bethell, former Parliamentary Under Secretary
Kizoo Invests in Rejuvenation Startup MoglingBio
October 26, 2022
Having received new funding from Kizoo Technology Capital in its first seed round, MoglingBio intends to further its research into the rejuvenation of aging stem cells, finding ways to stave
Magnitude Reveals a New Target for Aging Therapeutics
September 27, 2022
At Longevity Summit Dublin, Ethan Perlstein and Magnitude Biosciences revealed that a small molecule, SMER28, improves longevity in C. elegans, a common model of aging. Background One of the greatest
SENS Research Foundation Announces Ending Aging Forum 2022
August 15, 2022
SENS Research Foundation has announced this year’s Ending Aging Forum, which will be held through a virtual conference platform with an immersive environment. Come spend a wonderful and thought provoking
Bioreactor-Grown Mitochondria for Potential Anti-Aging
July 19, 2022
Researchers from the University of Connecticut, Stanford University, Université Laval Quebec, and NSU Florida have helped test large-scale exogenous mitochondrial transplants in animal disease models and in-vitro human cells. The
Second Rejuveron Company Transitions into Clinical Stage
July 12, 2022
Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, is pleased to announce that the first participant has been treated in Endogena Therapeutics’ phase
Molecule Raises $12.7 Million in Seed Funding for Biotech
June 30, 2022
Switzerland, Jun 30, 2022 – Molecule, a comprehensive funding and incubation ecosystem for early-stage biopharma research, announced this week they raised $12.7 million in seed funding. The round was led
Kizoo Portfolio Company Cellvie Closes $5.5M of Funding
February 8, 2023
The company cellvie, part of the portfolio of biotechnology holding company Kizoo Technology Capital, recently received $5.5 million to develop a mitochondria-based therapy. The full press release is included here. cellvie Inc., a leader in Therapeutic Mitochondria Transplantation (TMT), an approach developed at Harvard Medical School, closes a
Longevity Investors Lunch at Davos
January 24, 2023
A Longevity Investors Lunch hosted by Maximon, Longevity Investors Conference, and Biolytica has been hosted at a satellite event of the well-known Davos conference. The press release is included here. Longevity stays in the limelight on the streets of Davos for the second time during this
Open Longevity Foundation Announces Open Genes Database
January 24, 2023
Open Longevity Foundation has announced Open Genes, a database of longevity-associated genes and a tool for future anti-aging therapy development. The full press release is included here. Open Longevity Foundation released a novel database of genes involved in human aging and longevity — Open Genes. It
Gero Enters Research Collaboration with Pfizer
January 10, 2023
Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data. As part of this research collaboration, the companies will leverage Pfizer’s expertise and Gero’s
Immunis Begins Clinical Trial of Stem Cell Secretome
January 5, 2023
Intending to treat sarcopenia, the private biotechnology company Immunis has begun a human clinical trial of a stem cell secretome product that affects the immune system. The company’s full press release is included here. Immunis, Inc., a private biotech company developing an innovative treatment for age
Turn Biotechnologies Changes Paradigm in Skin Rejuvenation
December 6, 2022
Turn Biotechnologies has unveiled data at four industry conferences suggesting that a single ERA treatment may be more effective than combination therapies used today. Biomarker analysis demonstrates ERA’s regenerative impact on fibroblast proliferation, collagen VII production, and the eTurna™ lipid-based delivery platform proves groundbreakingly effective at
BioAge Announces Positive Results Against Muscle Atrophy
December 5, 2022
BioAge Labs has concluded a Phase 1b study in which human volunteers undergoing 10 days of bed rest were shown to have their related muscle atrophy significantly attenuated by BGE-105. RICHMOND, Calif.–(BUSINESS WIRE)–BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular
Longevity Biotech Fellowship Announces Launch
November 21, 2022
On Deck Longevity Biotech and the founders of LessDeath.org have collaborated to start the Longevity Biotech Fellowship, a new initiative focusing on bringing upcoming professionals into the longevity industry. The full press release is included below. Would you like to help accelerate the biggest revolution in
The Quantum Healthy Longevity Innovation Mission Launches
November 14, 2022
London. 14 November 2022. The National Innovation Centre for Ageing and Collider Health launch the Quantum Healthy Longevity Innovation Mission with a keynote by Lord Bethell, former Parliamentary Under Secretary of State for Technology, Innovation and Life Sciences, to shift ‘sickcare’ to a new model based
Kizoo Invests in Rejuvenation Startup MoglingBio
October 26, 2022
Having received new funding from Kizoo Technology Capital in its first seed round, MoglingBio intends to further its research into the rejuvenation of aging stem cells, finding ways to stave off stem cell exhaustion. Berlin/Ulm, Germany – October 26, 2022 – MoglingBio, a privately held biotech
Magnitude Reveals a New Target for Aging Therapeutics
September 27, 2022
At Longevity Summit Dublin, Ethan Perlstein and Magnitude Biosciences revealed that a small molecule, SMER28, improves longevity in C. elegans, a common model of aging. Background One of the greatest challenges for biomedical sciences is how to slow ageing. Ageing is the major risk factor for
SENS Research Foundation Announces Ending Aging Forum 2022
August 15, 2022
SENS Research Foundation has announced this year’s Ending Aging Forum, which will be held through a virtual conference platform with an immersive environment. Come spend a wonderful and thought provoking time with the team at SENS Research Foundation. This virtual event is your opportunity to hear
Bioreactor-Grown Mitochondria for Potential Anti-Aging
July 19, 2022
Researchers from the University of Connecticut, Stanford University, Université Laval Quebec, and NSU Florida have helped test large-scale exogenous mitochondrial transplants in animal disease models and in-vitro human cells. The results suggest broad efficacy for targeting the immune system, brain, retina, liver, skin, and systemic anti-aging.
Second Rejuveron Company Transitions into Clinical Stage
July 12, 2022
Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, is pleased to announce that the first participant has been treated in Endogena Therapeutics’ phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP).
Molecule Raises $12.7 Million in Seed Funding for Biotech
June 30, 2022
Switzerland, Jun 30, 2022 – Molecule, a comprehensive funding and incubation ecosystem for early-stage biopharma research, announced this week they raised $12.7 million in seed funding. The round was led by Northpond Ventures with participation from Shine Capital, 1kx, Fifty Years, KdT Ventures, BACKED VC, Inflection